Search
- Jan 4
Analyst Thursdays: Benjamin Burnett discusses names and topics on Stifel's 2024 'Key Controversies List'
Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution, Fate, CRISPR, and Disc.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A